Why Is ATAI Life Sciences Stock Trading Lower On Monday?
1. Recognify's trial data shows inidascamine's limited efficacy in cognitive impairment. 2. ATAI shares fell 9.38% following trial results announcement. 3. Inidascamine showed modest improvements but missed primary endpoints. 4. No serious side effects were found in trial participants. 5. Recognify plans to present more data at future scientific meetings.